Literature DB >> 17909015

Epigenetic inactivation of a cluster of genes flanking MLH1 in microsatellite-unstable colorectal cancer.

Megan P Hitchins1, Vita Ap Lin, Andrew Buckle, Kayfong Cheong, Nimita Halani, Su Ku, Chau-To Kwok, Deborah Packham, Catherine M Suter, Alan Meagher, Clare Stirzaker, Susan Clark, Nicholas J Hawkins, Robyn L Ward.   

Abstract

Biallelic promoter methylation and transcriptional silencing of the MLH1 gene occurs in the majority of sporadic colorectal cancers exhibiting microsatellite instability due to defective DNA mismatch repair. Long-range epigenetic silencing of contiguous genes has been found on chromosome 2q14 in colorectal cancer. We hypothesized that epigenetic silencing of MLH1 could occur on a regional scale affecting additional genes within 3p22, rather than as a focal event. We studied the levels of CpG island methylation and expression of multiple contiguous genes across a 4 Mb segment of 3p22 including MLH1 in microsatellite-unstable and -stable cancers, and their paired normal colonic mucosa. We found concordant CpG island hypermethylation, H3-K9 dimethylation and transcriptional silencing of MLH1 and multiple flanking genes spanning up to 2.4 Mb in microsatellite-unstable colorectal cancers. This region was interspersed with unmethylated genes, which were also transcriptionally repressed. Expression of both methylated and unmethylated genes was reactivated by methyltransferase and histone deacetylase inhibitors in a microsatellite-unstable colorectal carcinoma cell line. Two genes at the telomeric end of the region were also hypermethylated in microsatellite-stable cancers, adenomas, and at low levels in normal colonic mucosa from older individuals. Thus, the cluster of genes flanking MLH1 that was specifically methylated in the microsatellite-unstable group of cancers extended across 1.1 Mb. Our results show that coordinate epigenetic silencing extends across a large chromosomal region encompassing MLH1 in microsatellite-unstable colorectal cancers. Simultaneous epigenetic silencing of this cluster of 3p22 genes may contribute to the development or progression of this type of cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17909015     DOI: 10.1158/0008-5472.CAN-07-0869

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  Evidence of epigenetic regulation of the tumor suppressor gene cluster flanking RASSF1 in breast cancer cell lines.

Authors:  Erika da Costa Prando; Luciane Regina Cavalli; Cláudia Aparecida Rainho
Journal:  Epigenetics       Date:  2011-12       Impact factor: 4.528

2.  Aberrant silencing of cancer-related genes by CpG hypermethylation occurs independently of their spatial organization in the nucleus.

Authors:  Hariharan P Easwaran; Leander Van Neste; Leslie Cope; Subhojit Sen; Helai P Mohammad; Gayle J Pageau; Jeanne B Lawrence; James G Herman; Kornel E Schuebel; Stephen B Baylin
Journal:  Cancer Res       Date:  2010-08-24       Impact factor: 12.701

3.  Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity.

Authors:  Marcel W Coolen; Clare Stirzaker; Jenny Z Song; Aaron L Statham; Zena Kassir; Carlos S Moreno; Andrew N Young; Vijay Varma; Terence P Speed; Mark Cowley; Paul Lacaze; Warren Kaplan; Mark D Robinson; Susan J Clark
Journal:  Nat Cell Biol       Date:  2010-02-21       Impact factor: 28.824

4.  Parental age and risk of childhood cancer: a pooled analysis.

Authors:  Kimberly J Johnson; Susan E Carozza; Eric J Chow; Erin E Fox; Scott Horel; Colleen C McLaughlin; Beth A Mueller; Susan E Puumala; Peggy Reynolds; Julie Von Behren; Logan G Spector
Journal:  Epidemiology       Date:  2009-07       Impact factor: 4.822

5.  Long-range epigenetic silencing of chromosome 5q31 protocadherins is involved in early and late stages of colorectal tumorigenesis through modulation of oncogenic pathways.

Authors:  A R Dallosso; B Øster; A Greenhough; K Thorsen; T J Curry; C Owen; A L Hancock; M Szemes; C Paraskeva; M Frank; C L Andersen; K Malik
Journal:  Oncogene       Date:  2012-01-16       Impact factor: 9.867

6.  Methylation of a single intronic CpG mediates expression silencing of the PMP24 gene in prostate cancer.

Authors:  Xiang Zhang; Mengchu Wu; Hong Xiao; Ming-Tsung Lee; Linda Levin; Yuet-Kin Leung; Shuk-Mei Ho
Journal:  Prostate       Date:  2010-05-15       Impact factor: 4.104

7.  Specific variants in the MLH1 gene region may drive DNA methylation, loss of protein expression, and MSI-H colorectal cancer.

Authors:  Miralem Mrkonjic; Nicole M Roslin; Celia M Greenwood; Stavroula Raptis; Aaron Pollett; Peter W Laird; Vaijayanti V Pethe; Theodore Chiang; Darshana Daftary; Elizabeth Dicks; Stephen N Thibodeau; Steven Gallinger; Patrick S Parfrey; H Banfield Younghusband; John D Potter; Thomas J Hudson; John R McLaughlin; Roger C Green; Brent W Zanke; Polly A Newcomb; Andrew D Paterson; Bharati Bapat
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

8.  Agglomerative epigenetic aberrations are a common event in human breast cancer.

Authors:  Petr Novak; Taylor Jensen; Marc M Oshiro; George S Watts; Christina J Kim; Bernard W Futscher
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

9.  Long-range epigenetic silencing at 2q14.2 affects most human colorectal cancers and may have application as a non-invasive biomarker of disease.

Authors:  R Mayor; L Casadomé; D Azuara; V Moreno; S J Clark; G Capellà; M A Peinado
Journal:  Br J Cancer       Date:  2009-04-21       Impact factor: 7.640

10.  Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms' tumor.

Authors:  Anthony R Dallosso; Anne L Hancock; Marianna Szemes; Kim Moorwood; Laxmi Chilukamarri; Hsin-Hao Tsai; Abby Sarkar; Jonathan Barasch; Raisa Vuononvirta; Chris Jones; Kathy Pritchard-Jones; Brigitte Royer-Pokora; Sean Bong Lee; Ceris Owen; Sally Malik; Yi Feng; Marcus Frank; Andrew Ward; Keith W Brown; Karim Malik
Journal:  PLoS Genet       Date:  2009-11-26       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.